T cell responses to whole SARS coronavirus in humans

Journal of Immunology

Volumn 181, Issue 8, 2008, Pages 5490-5500

  Li, Chris Ka Fai ^a   Wu, Hao ^b   Yan, Huiping ^b   Ma, Shiwu ^c   Wang, Lili ^a   Zhang, Mingxia ^c   Tang, Xiaoping ^d   Temperton, Nigel J ^e   Weiss, Robin A ^e   Brenchley, Jason M ^f   Douek, Daniel C ^f   Mongkolsapaya, Juthathip ^g   Tran, Bac Hai ^g   Lin, Chen Lung Steve ^g   Screaton, Gavin R ^g   Hou, Jin Lin ^c   McMichael, Andrew J ^a   Xu, Xiao Ning ^a,h  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d Guangzhou Number 12 Hospital   (China)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g HAMMERSMITH HOSPITAL   (United Kingdom)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD45RO ANTIGEN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEUTRALIZING ANTIBODY; PEPTIDE; PROTEOME; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TUMOR NECROSIS FACTOR ALPHA; CD45 ANTIGEN; CYTOKINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CONVALESCENCE; CYTOKINE PRODUCTION; CYTOMETRY; DEGRANULATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE; TH2 CELL; CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, CD27; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; PROTEOME; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TH2 CELLS; VIRAL VACCINES;

EID: 54049137978     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.8.5490     Document Type: Article

References (34)

1. Zhao, G. P. 2007. SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos. Trans. R Soc. Lond. B 362: 1063-1081.
2. Shi, Z., and Z. Hu. 2007. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 133: 74-87.
3. Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, et al. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676-679. (Pubitemid 41528160)
4. Stockman, L. J., R. Bellamy, and P. Garner. 2006. SARS: systematic review of treatment effects. PLoS Med. 3: e343.
5. Chu, C. M., L. L. Poon, V. C. Cheng, K. S. Chan, I. F. Hung, M. M. Wong, K. H. Chan, W. S. Leung, B. S. Tang, V. L. Chan, et al. 2004. Initial viral load and the outcomes of SARS. Canadian Medical Association Journal 171: 1349-1352.
6. Chen, J., and K. Subbarao. 2007. The immunobiology of SARS*. Annu. Rev. Immunol. 25: 443-472.
7. Cameron, M. J., L. Ran, L. Xu, A. Danesh, J. F. Bermejo-Martin, C. M. Cameron, M. P. Muller, W. L. Gold, S. E. Richardson, S. M. Poutanen, et al. 2007. Interferon- mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81: 8692-8706.
8. Temperton, N. J., P. K. Chan, G. Simmons, M. C. Zambon, R. S. Tedder, Y. Takeuchi, and R. A. Weiss. 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg. Infect. Dis. 11: 411-416. (Pubitemid 40315726)
9. Ho, M. S., W. J. Chen, H. Y. Chen, S. F. Lin, M. C. Wang, J. Di, Y. T. Lu, C. L. Liu, S. C. Chang, C. L. Chao, et al. 2005. Neutralizing antibody response and SARS severity. Emerg. Infect. Dis. 11: 1730-1737.
10. Roberts, A., E. W. Lamirande, L. Vogel, J. P. Jackson, C. D. Paddock, J. Guarner, S. R. Zaki, T. Sheahan, R. Baric, and K. Subbarao. 2007. Animal models and vaccines for SARS-CoV infection. Virus Res. 133: 20-32.
11. Yang, Z. Y., W. P. Kong, Y. Huang, A. Roberts, B. R. Murphy, K. Subbarao, and G. J. Nabel. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561-564. (Pubitemid 38480539)
12. Zhu, Z., S. Chakraborti, Y. He, A. Roberts, T. Sheahan, X. Xiao, L. E. Hensley, P. Prabakaran, B. Rockx, I. A. Sidorov, et al. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 104: 12123-12128. (Pubitemid 47185640)
13. Hogan, R. J. 2006. Are nonhuman primates good models for SARS? PLoS Med 3:e411; author reply e415.
14. Perlman, S., and A. A. Dandekar. 2005. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5: 917-927. (Pubitemid 41746761)
15. Weingartl, H., M. Czub, S. Czub, J. Neufeld, P. Marszal, J. Gren, G. Smith, S. Jones, R. Proulx, Y. Deschambault, et al. 2004. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78: 12672-12676. (Pubitemid 39458786)
16. Yang, Z. Y., H. C. Werner, W. P. Kong, K. Leung, E. Traggiai, A. Lanzavecchia, and G. J. Nabel. 2005. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. USA 102: 797-801. (Pubitemid 40282745)
17. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422-434.
18. Chattopadhyay, P. K., D. A. Price, T. F. Harper, M. R. Betts, J. Yu, E. Gostick, S. P. Perfetto, P. Goepfert, R. A. Koup, S. C. De Rosa, et al. 2006. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat. Med. 12: 972-977.
19. WHO. 2003. Case Definitions for Surveillance of Severe Acute Respiratory Syndrome (SARS). casedefinition/en/. WHO, http://www.who.int/csr/sars/.
20. CDC. 2003. Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) CDC, Version 2 2003 at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5217a5.ht
21. Chen, X., B. Zhou, M. Li, X. Liang, H. Wang, G. Yang, H. Wang, and X. Le. 2004. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J. Infect. Dis. 189: 1158-1163.
22. Li, T., J. Xie, Y. He, H. Fan, L. Baril, Z. Qiu, Y. Han, W. Xu, W. Zhang, H. You, et al. 2006. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS ONE. 1:e24.
23. Addo, M. M., X. G. Yu, A. Rathod, D. Cohen, R. L. Eldridge, D. Strick, M. N. Johnston, C. Corcoran, A. G. Wurcel, C. A. Fitzpatrick, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77: 2081-2092.
24. Goulder, P. J., M. M. Addo, M. A. Altfeld, E. S. Rosenberg, Y. Tang, U. Govender, N. Mngqundaniso, K. Annamalai, T. U. Vogel, M. Hammond, et al. 2001. Rapid definition of five novel HLA-A*3002-restricted human immunode- ficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J. Virol. 75: 1339-1347.
25. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5: 518-525.
26. Donnelly, C. A., A. C. Ghani, G. M. Leung, A. J. Hedley, C. Fraser, S. Riley, L. J. Abu-Raddad, L. M. Ho, T. Q. Thach, P. Chau, et al. 2003. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 361: 1761-1766. (Pubitemid 36638422)
27. Han, S. N., and S. N. Meydani. 2000. Antioxidants, cytokines, and influenza infection in aged mice and elderly humans. J. Infect. Dis. 182 Suppl 1:S74-S80.
28. + T-cell epitope SSp-1 of SARS-CoV spike protein. Blood 104: 200-206.
29. Zhou, M., D. Xu, X. Li, H. Li, M. Shan, J. Tang, M. Wang, F. S. Wang, X. Zhu, H. Tao, et al. 2006. Screening and identification of severe acute respiratory syndrome- associated coronavirus-specific CTL epitopes. J. Immunol. 177: 2138-2145. (Pubitemid 44200972)
30. Zhao, J., Q. Huang, W. Wang, Y. Zhang, P. Lv, and X. M. Gao. 2007. Identification and characterization of dominant helper T-cell epitopes in the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 81: 6079-6088. (Pubitemid 46847043)
31. Mitchison, N. A. 2004. T-cell-B-cell cooperation. Nat. Rev. Immunol. 4: 308-312.
32. Rota, P. A., M. S. Oberste, S. S. Monroe, W. A. Nix, R. Campagnoli, J. P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M. H. Chen, et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-1399. (Pubitemid 36638152)
33. de Jong, M. D., C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith, T. N. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12: 1203-1207. (Pubitemid 44527358)
34. Peiris, J. S., C. M. Chu, V. C. Cheng, K. S. Chan, I. F. Hung, L. L. Poon, K. I. Law, B. S. Tang, T. Y. Hon, C. S. Chan, et al. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.